Posted by Michael Wonder on 25 Aug 2022
Children with chronic graft versus host disease may now be prescribed Imbruvica (ibrutinib)
24 August 2022 - This is the first approved treatment option for children with cGVHD under 12 years of age and the only Bruton's tyrosine kinase inhibitor treatment for a paediatric patient population.
AbbVie today announced that the U.S. FDA approved the use of Imbruvica (ibrutinib) for the treatment of paediatric patients one year and older with chronic graft versus host disease after failure of one or more lines of systemic therapy.
